Biotechnology firm Creative Biolabs is advancing microbial therapeutics through sophisticated genetic engineering techniques that transform common bacteria into potential medical treatment platforms. By precisely modifying microorganisms' genetic structures, researchers can develop novel approaches to treating challenging medical conditions.
The company's primary focus involves engineering therapeutic strains with enhanced capabilities for targeted drug delivery and disease treatment. Using genomics and molecular biology tools, scientists can modify bacteria like Lactobacillus and Escherichia coli Nissle 1917 (EcN) to carry therapeutic molecules and target specific medical challenges.
One breakthrough technology is the synchronized lysis circuit (SLC), which enables engineered bacteria to release therapeutic factors at predetermined intervals. This approach allows for precise targeting of specific cells, such as tumor cells, while minimizing damage to surrounding healthy tissue.
For instance, the company has successfully engineered an EcN strain capable of overproducing molecules that activate programmed cell death and inhibit blood vessel formation in tumors. Similarly, Lactobacillus can be modified to deliver anti-inflammatory cytokines and antioxidant enzymes.
The potential applications of these engineered strains are extensive, spanning inflammatory bowel disease, cancer, diabetes, and infectious diseases. By transforming well-characterized, safe bacterial strains into sophisticated therapeutic tools, Creative Biolabs is pushing the boundaries of personalized medical treatments.
